Orchestra Biomed Holdings revenue was $2.64M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $253.0k, down 74.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, OBIO annual revenue was $2.6M, with -4.4% growth year-over-year.
OBIO past revenue growth
How has OBIO's revenue growth performed historically?
Orchestra Biomed Holdings (NASDAQ: OBIO) reported Q4 2024 revenue of $253.00 thousand up 3.44% year over year. In the same quarter last year, Orchestra Biomed Holdings's revenue was $262.00 thousand.
What was Orchestra Biomed Holdings's revenue in 2024?
Orchestra Biomed Holdings's annual revenue for the twelve months ending Dec 31, 2024 was $2.64 million, a 4.42% decrease year over year.
How much does Orchestra Biomed Holdings make in a day?
Based on Orchestra Biomed Holdings annual revenue for the past four years, OBIO makes an average of $5,581.51 per day.
What was Orchestra Biomed Holdings's annual revenue growth in the past year?
As of Q2 2025, Orchestra Biomed Holdings's revenue has grown -4.42% year over year. This is 502.11 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Orchestra Biomed Holdings's revenue in the past year totaled $2.64 million.
How much does Orchestra Biomed Holdings make in a year?
Orchestra Biomed Holdings's revenue by year for the past four years is:
Orchestra Biomed Holdings's revenue for the twelve months ending Dec 31, 2024 was $2.64 million, a 4.42% decrease year over year.
Orchestra Biomed Holdings's annual revenue for Dec 31, 2023 was $2.76 million, a 21.88% decrease from 2022.
Orchestra Biomed Holdings's annual revenue for 2022 was $3.53 million, a 551.79% decrease from 2021.
Orchestra Biomed Holdings's annual revenue for 2021 was -$782.00 thousand, a 113.71% decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.